Millipore Sigma Vibrant Logo

533965 IAP Antagonist, BV6 - CAS 1001600-56-1 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
1001600-56-1C₇₀H₉₆N₁₀O₈

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.33965.0001
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA bivalent SMAC mimetic that antagonizes cIAP1 and XIAP interaction with initiator caspases and triggers their proteasomal degradation. Shown to rapidly deplete levels of cIAP1 and XIAP in HCC193 (at 1 µM) and H460 (at 5 µM) lung cancer cell lines. Levels of cIAP1 are reduced within an hour following treatment while XIAP depletion takes up to 24 h. Effectively reduces the viability of HCC193 (IC50 = 7.2 µM) and H460 (IC50 = 30 µM) cells and synergistically enhances their sensitivity to radiation treatment. Reported to increase apoptosis via caspase-8 activation in HCC193 cells (~ 1 µM) and via caspase-9 in H460 cells (~ 5 µM). Also shown to increase the secretion of TNFa in HCC193 cells in a dose-dependent manner. Also enhances cytokine-induced killer (CIK) cell-mediated cytotoxicity against multiple hematological (H9, THP-1, Tanoue) and solid malignant cells (RH1, RH30, and TE671).

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number533965
      Brand Family Calbiochem®
      Synonyms(S,S,2S,2ʹS)-N,Nʹ-((2S,2ʹS)-(hexane-1,6-diylbis(azanediyl))bis(3-oxo-1,1-diphenylpropane-3,2-diyl))bis(1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide)
      DescriptionIAP Antagonist, BV6
      References
      ReferencesRettinger, E., et al. 2014. Front in Pediatr. 2, 75.
      Li, W., et al. 2011. J. Thorac. Oncol. 6, 1801.
      Product Information
      CAS number1001600-56-1
      FormWhite powder
      FormulationSupplied as a trifluoroacetate salt.
      Hill FormulaC₇₀H₉₆N₁₀O₈
      Chemical formulaC₇₀H₉₆N₁₀O₈
      Hygroscopic Hygroscopic
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetIAP
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      5.33965.0001 04055977281644

      Documentation

      IAP Antagonist, BV6 - CAS 1001600-56-1 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      IAP Antagonist, BV6 - CAS 1001600-56-1 - Calbiochem Certificates of Analysis

      TitleLot Number
      533965

      References

      Reference overview
      Rettinger, E., et al. 2014. Front in Pediatr. 2, 75.
      Li, W., et al. 2011. J. Thorac. Oncol. 6, 1801.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-June-2016 JSW
      Synonyms(S,S,2S,2ʹS)-N,Nʹ-((2S,2ʹS)-(hexane-1,6-diylbis(azanediyl))bis(3-oxo-1,1-diphenylpropane-3,2-diyl))bis(1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide)
      DescriptionA bivalent SMAC mimetic that antagonizes cIAP1 and XIAP interaction with initiator caspases and triggers their proteasomal degradation. Shown to rapidly deplete levels of cIAP1 and XIAP in HCC193 (at 1 µM) and H460 (at 5 µM) lung cancer cell lines. Levels of cIAP1 are reduced within an hour following treatment while XIAP depletion takes up to 24 h. Effectively reduces the viability of HCC193 (IC50 = 7.2 µM) and H460 (IC50 = 30 µM) cells and synergistically enhances their sensitivity to radiation treatment. Reported to increase apoptosis via caspase-8 activation in HCC193 cells (~ 1 µM) and via caspase-9 in H460 cells (~ 5 µM). Also shown to increase the secretion of TNFa in HCC193 cells in a dose-dependent manner. Also enhances cytokine-induced killer (CIK) cell-mediated cytotoxicity against multiple hematological (H9, THP-1, Tanoue) and solid malignant cells (RH1, RH30, and TE671).
      FormWhite powder
      FormulationSupplied as a trifluoroacetate salt.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1001600-56-1
      Chemical formulaC₇₀H₉₆N₁₀O₈
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesRettinger, E., et al. 2014. Front in Pediatr. 2, 75.
      Li, W., et al. 2011. J. Thorac. Oncol. 6, 1801.